KURA - Kura Oncology, Inc. -  [ ]

Ticker Details
Kura Oncology, Inc.
Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
IPO Date: September 16, 2015
Sector: Healthcare
Industry: Biotech
Market Cap: $1.06B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.41 | 3.06%
Avg Daily Range (30 D): $0.34 | 3.18%
Avg Daily Range (90 D): $0.30 | 3.00%
Institutional Daily Volume
Avg Daily Volume: .59M
Avg Daily Volume (30 D): 1.3M
Avg Daily Volume (90 D): 1.44M
Trade Size
Avg Trade Size (Sh.): 91
Avg Trade Size (Sh.) (30 D): 80
Avg Trade Size (Sh.) (90 D): 81
Institutional Trades
Total Institutional Trades: 3,210
Avg Institutional Trade: $1.85M
Avg Institutional Trade (30 D): $2.07M
Avg Institutional Trade (90 D): $2.05M
Avg Institutional Trade Volume: .13M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2M
Avg Closing Trade (30 D): $2.41M
Avg Closing Trade (90 D): $2.45M
Avg Closing Volume: 142.41K
 
News
Aug 5, 2026 @ 11:30 AM
Kura Oncology to Report Second Quarter Financial R...
Source: Na
Apr 24, 2026 @ 12:00 PM
Kyowa Kirin and Kura Oncology Initiate Japanese Ph...
Source: Na
Apr 17, 2026 @ 10:00 AM
Kura Oncology Reports Darlifarnib Plus Cabozantini...
Source: Na
Apr 3, 2026 @ 11:30 AM
Kura Oncology Reports Inducement Grants Under Nasd...
Source: Na
Dec 4, 2025 @ 5:20 PM
Blood Cancer Therapeutics Reach Critical Commercia...
Source: Prnewswire
Financials
  TTM Q1 2026 Q4 2025
Basic EPS $-.77 $-.83 $-.92
Diluted EPS $-.77 $-.83 $-.92
Revenue $20.87M $18.27M $17.34M
Gross Profit $20.63M $18M
Net Income / Loss $-68.33M $-73.33M $-81M
Operating Income / Loss $-73.01M $-78.82M $-86.27M
Cost of Revenue $.24M $.26M
Net Cash Flow $31.16M $-110.02M $53.81M
PE Ratio